Venture Capital

Cyera: $400 Million Series F At $9 Billion Valuation Raised As Enterprises Ramp Up AI Security

By Amit Chowdhry ● Jan 8, 2026

Cyera, an AI and data security company, has raised $400 million in a Series F funding round led by funds managed by Blackstone, pushing the company’s valuation to $9 billion and bringing total funding to more than $1.7 billion. The financing comes roughly six months after Cyera’s prior round and marks a valuation that the company says has tripled over the past year.

ViCentra Expands Series D To $98 Million To Scale Kaleido Insulin Patch Pump Commercialization

By Amit Chowdhry ● Jan 8, 2026

ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, said it has added $13 million in new capital to its Series D financing, bringing the total round to $98 million. The second close includes new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, as well as increased backing from existing investor Innovation Industries.

Sibros Raises $9 Million in Growth Financing

By Amit Chowdhry ● Jan 8, 2026

Sibros has raised $9 million in a growth financing round, with Niterra Co., Ltd. participating in the investment as the software-defined vehicle (SDV) platform provider looks to expand product capabilities and scale commercialization.

TECregen Raises CHF 10 Million Seed Round, Names Dr. Bo Rode Hansen Chairman

By Amit Chowdhry ● Jan 8, 2026

Basel, Switzerland-based TECregen has raised CHF 10 million (approximately €10.7 million / $12.6 million) in seed financing to advance a new class of thymus-rejuvenating biologics aimed at restoring immune function by rejuvenating thymic epithelial cells (TECs). The round was led by the Boehringer Ingelheim Venture Fund (BIVF) and included participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank.

Enable Injections Announces $30 Million Sanofi Investment To Expand enFuse On-Body Injector Manufacturing

By Amit Chowdhry ● Jan 8, 2026

Enable Injections announced that Sanofi is making a $30 million investment in the Cincinnati-based drug delivery company to accelerate a manufacturing build-out, bolster supply chain capabilities, and support commercial growth for its enFuse on-body delivery system.

Protege: $30 Million Raised To Expand Real-World Data Access For AI Development

By Amit Chowdhry ● Jan 8, 2026

Protege, an AI data platform focused on unlocking trusted, real-world datasets at scale, has raised a $30 million Series A round led by Andreessen Horowitz (a16z). The financing expands the company’s previously announced $25 million Series A from August 2025 and brings total funding to $65 million since Protege’s founding in 2024. Returning investors include Footwork, CRV, Bloomberg Beta, Flex Capital, Shaper Capital, and others.

Tenax Aerospace Completes Refinancing, Buys Out Bain Capital Credit And Consolidates NTC Group Ownership

By Amit Chowdhry ● Jan 8, 2026

Tenax Aerospace, a provider of special mission aircraft and related services to U.S. government and commercial customers, said it has completed a refinancing that includes the buyout of its junior capital partner, Bain Capital Credit, consolidating ownership of the business under NTC Group.

Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform

By Amit Chowdhry ● Jan 8, 2026

Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types and to expand a broader pipeline built on its Helicon peptide platform. The round was co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors. Parabilis said new investors in the financing included Frazier Life Sciences, Soleus Capital, and a life science-dedicated investment fund, alongside participation from a broad syndicate of existing backers including venBio Partners, Cormorant Asset Management, ARCH Venture Partners, GV, accounts advised by T. Rowe Price Associates, Marshall Wace, General Catalyst, Invus, Farallon Capital Management, Foresite Capital, Rock Springs Capital, HBM Healthcare, Samsara BioCapital, Catalio Capital Management, and others.

NovaWave Capital Adds New Investors And Unveils Arizona “WaveX” AI Venture Studio With State Commerce Authority

By Amit Chowdhry ● Jan 8, 2026

NovaWave Capital announced it has reached a new milestone for its NovaWave Fund I generation, adding AZ Venture Capital Inc. and Sunny Day Sports as incoming investors, as it expands its public-private capital base to support innovation across the U.S.